The EuroNet Paediatric Hodgkin Network – Modern Imaging Data Management for Real Time Central Review in Multicentre Trials

Kurch, Lars; Mauz‐Körholz, Christine; Bertling, S.; Wallinder, M.; Kamińska, Marzena; Marwede, Dirk; Tchavdarova, L; Georgi, Thomas; Elsner, Andreas; Barthel, Andreas; Stoevesandt, Dietrich; Hasenclever, Dirk; Sattler, Bernhard; Sabri, Osama; Körholz, Dieter; Kluge, Regine

doi:10.1055/s-0033-1354416

Cited by 27 publications

(25 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This trial recruited 2,111 patients with classical HL (all stages) from 18 European countries between 2007 and 2013 [ 91 ] ( http://clinicaltrials.gov/ct/show/NCT00433459:2012 ). A Paediatric Hodgkin Network was created to transfer images for central review [ 92 ]. Interim PET was performed after two cycles of vincristine, etoposide, prednisone and doxorubicin (OEPA).…”

Section: Response-adapted Treatment Using Fdg Petmentioning

confidence: 99%

FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas

Barrington

Kluge

2017

Eur J Nucl Med Mol Imaging

215

187

View full text Add to dashboard Cite

PET using 18F-FDG for treatment monitoring in patients with lymphoma is one of the most well-developed clinical applications. PET/CT is nowadays used during treatment to assess chemosensitivity, with response-adapted therapy given according to ‘interim’ PET in clinical practice to adults and children with Hodgkin lymphoma. PET is also used to assess remission from disease and to predict prognosis in the pretransplant setting. Mature data have been reported for the common subtypes of aggressive B-cell lymphomas, with more recent data also supporting the use of PET for response assessment in T-cell lymphomas. The Deauville five-point scale incorporating the Deauville criteria (DC) is recommended for response assessment in international guidelines. FDG uptake is graded in relation to the reference regions of normal mediastinum and liver. The DC have been validated in most lymphoma subtypes. The DC permit the threshold for adequate or inadequate response to be adapted according to the clinical context or research question. It is important for PET readers to understand how the DC have been applied in response-adapted trials for correct interpretation and discussion with the multidisciplinary team. Quantitative methods to perform PET in standardized ways have also been developed which may further improve response assessment including a quantitative extension to the DC (qPET). This may have advantages in providing a continuous scale to refine the threshold for adequate/inadequate response in specific clinical situations or treatment optimization in trials. qPET is also less observer-dependent and limits the problem of optical misinterpretation due to the influence of background activity.

show abstract

Section: Response-adapted Treatment Using Fdg Petmentioning

confidence: 99%

FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas

Barrington

Kluge

2017

Eur J Nucl Med Mol Imaging

215

187

View full text Add to dashboard Cite

show abstract

“…Therefore, it seems necessary to reevaluate seemingly lucrative biomarkers and define new prognostic biomarkers or gene expression signatures for pediatric Hodgkin lymphoma patients. Such studies require large patient numbers and should, therefore, be performed concomitantly to clinical studies such as the EuroNet pediatric HL trials [247].…”

Section: Discussionmentioning

confidence: 99%

Prognostic Biomarkers for Hodgkin Lymphoma

Staege

Kewitz

Bernig

et al. 2015

Pediatric Hematology and Oncology

View full text Add to dashboard Cite

The prognosis of patients with classical Hodgkin lymphoma following chemo- and radiotherapy has been excellent during the last 4 decades. However, the development of secondary malignancies is of major concern. Therefore, the reduction of radiotherapy application is a major objective of ongoing clinical trials. De-escalation of treatment may increase the risk of relapses and thus may lead to reappearance of prognostic factors. Prognostic biomarkers might help to identify patients who are at increased risk of relapse. This review summarizes the current knowledge about potential prognostic biomarkers for patients with classical Hodgkin lymphoma.

show abstract

“…before radiotherapy, was mandatory. Following review of results of gPoH-HD-2002/VecoPa pilot trial 3 the response assessment, the central review board provided radiotherapy recommendations [22]. The definition of disease stages was adopted according to the Ann Arbor Conference classification.…”

Section: Ethics Statementmentioning

confidence: 99%

Feasibility of VECOPA, a dose-intensive chemotherapy regimen for children and adolescents with intermediate and advanced stage Hodgkin lymphoma: results of the GPOH-HD-2002/VECOPA pilot trial

Mauz‐Körholz

Hasenclever²,

Holzendorf

et al. 2014

Leukemia & Lymphoma

View full text Add to dashboard Cite

The GPOH-HD (Gesellschaft für Pädiatrische Onkologie und Hämatologie-Hodgkin Disease) strategy for children and adolescents with intermediate and advanced stage Hodgkin lymphoma is based on two induction cycles of OEPA (vincristine, etoposide, prednisone, doxorubicin) followed by COPP (cyclophosphamide, vincristine, procarbazine, prednisone) or COPDAC (cyclophosphamide, vincristine, prednisone, dacarbazine) consolidation. The feasibility and efficacy of an intensified procarbazine-free consolidation regimen VECOPA (vinblastine, etoposide, cyclophosphamide, vincristine, prednisone, doxorubicin) were investigated. Following two OEPA and one or two VECOPA cycles, involved field radiotherapy was applied. The main endpoint was feasibility. Secondary endpoints were toxicity, proportion of delayed cycles, granulocyte-colony stimulating factor use, and event-free and overall survival. The regimen was well tolerated with mostly hematotoxicity exceeding Common Toxicity Criteria grade 2. In most patients with advanced stage the second VECOPA cycle was delayed despite hematopoietic recovery and absence of serious adverse events. Event-free survival at 36 months was 0.86 (95% confidence interval 0.70-1). The VECOPA regimen is effective and tolerable. However, its time-intensification was not fully exploited within this trial.

show abstract

The EuroNet Paediatric Hodgkin Network – Modern Imaging Data Management for Real Time Central Review in Multicentre Trials

Cited by 27 publications

References 5 publications

FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas

FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas

Prognostic Biomarkers for Hodgkin Lymphoma

Feasibility of VECOPA, a dose-intensive chemotherapy regimen for children and adolescents with intermediate and advanced stage Hodgkin lymphoma: results of the GPOH-HD-2002/VECOPA pilot trial

Contact Info

Product

Resources

About